81574-49-4

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
2,4-dimethoxy-3-methylbenzoic acid is utilized as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its chemical structure allows for the development of new compounds with potential therapeutic and pesticidal properties, enhancing the effectiveness of treatments and crop protection.
Used in Dyes and Pigments Production:
In the dye and pigment industry, 2,4-dimethoxy-3-methylbenzoic acid serves as a crucial raw material. Its unique chemical properties enable the creation of a wide range of dyes and pigments with specific color characteristics, catering to various applications in textiles, plastics, and other industries.
Used in Organic Electronics and Materials Science:
2,4-dimethoxy-3-methylbenzoic acid is employed as a component in the development of organic electronic devices and materials. Its chemical structure and properties make it suitable for use in organic light-emitting diodes (OLEDs), organic solar cells, and other electronic components, contributing to advances in flexible and eco-friendly electronics.
Used in Biological Activity Research:
2,4-dimethoxy-3-methylbenzoic acid has been studied for its potential biological activities, such as antioxidant and anti-inflammatory properties. As a result, it is used as a subject of research in the field of biochemistry and pharmacology, with the aim of discovering new therapeutic agents and understanding their mechanisms of action.

Upstream product

• 103988-44-9 2-Acetoxy-6-acetyl-2-methyl-cyclohexadienon 
• 39503-26-9 5-carbomethoxy-6-hydroxysalicylaldehyde 
• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 81574-50-7 2,4-Dimethoxy-3-methyl-benzaldehyde oxime 
• 6248-20-0 2,4-dihydroxy-3-methylbenzaldehyde 
• 608-25-3 2-methylbenzene-1,3-diol 
• 107625-52-5 2,4-Diacetoxy-3-methyl-acetophenon 
• 77-78-1 dimethyl sulfate 
• 81574-51-8 2,4-dimethoxy-3-methylbenzonitrile 
• 7149-92-0 2,4-dimethoxy-3-methylbenzaldehyde 
• 116371-82-5 2-hydroxy-4-methoxy-3-methylbenzoic acid 
• 855641-82-6 3-formyl-2,4-dimethoxy-benzoic acid 
• 116386-94-8 methyl 2-hydroxy-4-methoxy-3-methylbenzoate 
• 33662-58-7 methyl 2,4-dihydroxy-3-methylbenzoate 

Downstream Products

• 25576-97-0 2,3,6-trimethoxytoluene 
• 169775-23-9 5-bromo-3-methyl-1,2,4-trimethoxybenzene 
• 185981-77-5 1-Iodo-2,4,5-trimethoxy-3-methyl-benzene 
• 185981-74-2 1-(benzyloxy)-2,4-dimethoxy-3-methylbenzene 
• 185981-82-2 1-(benzyloxy)-5-bromo-2,4-dimethoxy-3-methylbenzene 
• 942132-75-4 C₂₅H₃₄N₂O₇ 
• 942132-73-2 C₂₅H₃₄N₂O₆ 
• 74628-39-0 methyl 2,4-dimethoxy-6-(2,4,6-trimethoxy-3-methylphenoxy)-3-methylbenzoate 
• 74628-38-9 methyl 2,4-dimethoxy-6-(2,4,6-trimethoxyphenoxy)-3-methylbenzoate 
• 81574-61-0 methyl 6-(4-hydroxy-2,6-dimethoxy-3-methylphenoxy)-2,4-dimethoxy-3-methylbenzoate 
• 81574-64-3 methyl 6-(4-hydroxy-2,6-dimethoxyphenoxy)-2,4-dimethoxy-3-methylbenzoate 
• 81574-63-2 6-(4-hydroxy-2,6-dimethoxyphenoxy)-2,4-dimethoxy-3-methylbenzoic acid 
• 81574-66-5 4',6-dihydroxy-2,2',4,6'-tetramethoxy-3-methylbenzophenone 
• 81574-53-0 methyl 2-hydroxy-4-methoxy-3-methyl-5-nitrobenzoate 

Relevant academic research and scientific papers

Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors

The cumulative evidence supports STAT3, a transcriptional mediator of oncogenic signaling, as a therapeutic target in cancer. The development of STAT3 inhibitors remain an active area of research as no inhibitors have yet to be approved for cancer treatment. In a continuing effort to develop more potent STAT3 inhibitors based on our previously identified hit compound 16w, a series of benzothiazole derivatives with unique binding mode in SH2 domain of STAT3 were designed, synthesized and biologically evaluated. Of note, compound B19 demonstrated excellent activity against IL-6/STAT3 signaling pathway with the IC50 value as low as 0.067 μM as determined by a luciferase reporter assay. Moreover, multiple compounds displayed potent antiproliferative activity against MDA-MB-468 and JAK2 mutant HEL cell lines. Further biochemical study using Western blot assay indicated that B19 blocked the phosphorylation of STAT3 at Tyr 705 and Ser 727 and thus suppressed STAT3-mediated gene expression of c-MYC and MCL-1. Simultaneously, it induced cancer cell G2/M phase arrest and apoptosis both in MDA-MB-468 and HEL cell lines. Finally, molecular docking study along with surface plasmon resonance (SPR) and fluorescence polarization (FP) assays disclosed the binding mode of B19 in STAT3 SH2 domain. Taken together, our finding suggests that B19 is a promising therapeutic STAT3 inhibitor for cancer treatment.

Biaryl formation using the Suzuki protocol: Considerations of base, halide, and protecting group

The generation of aryl anions prior to quenching with a trialkyl berate has been shown to be sensitive to the composition of the aryl substrate. Aryl iodides containing remote benzyl ether substituents undergo trans-metallation with sec-BuLi to cleanly give the desired aryl anions whereas the corresponding bromides afford appreciable quantities of dianionic intermediates. The aryl boronic acids derived from alkylation of these anions subsequently undergo a palladium mediated coupling with aryl halides to provide good yields of the desired biaryls. Copyright (C) 1996 Elsevier Science Ltd.

Depsidone Synthesis. Part 21. A New Synthesis of Grisa-2',5'-diene-3,4'-diones

Treatment of suitably substituted methyl 2-phenoxybenzoates with titanium(IV) chloride and dry hydrogen chloride afforded grisa-2',5'-diene-3,4'-diones in high yield.The structures of these compounds followed from their thermal stability, their methanolysis to methyl 2-(4-hydroxyphenoxy)benzoates, and their reductive cleavage to 2,4'-dihydrobenzophenones.Treatment of the benzophenones with base gave xanthones.An attempt to synthesize dehydrogriseofulvin (1) by this method failed.